The Ministry of Health and Family Welfare of Bangladesh has issued a directive requiring prior approval from the Directorate General of Drug Administration (DGDA) before commercial banks can open letters of credit (LCs) for importing supplement products. The circular, also endorsed by the central bank, was announced following a government notification issued on Wednesday.
According to the official notice, under the Drugs and Cosmetics Act, 2023, registration or prior approval from the DGDA is mandatory for the production, import, export, sale, and distribution of dietary, herbal, nutritional, medical, or therapeutic supplements. Violating these provisions constitutes a punishable offense. The directive follows incidents where some importers brought in supplements without approval, leading customs authorities to halt clearance. Subsequent legal proceedings reached the Supreme Court’s Appellate Division, which allowed conditional clearance under the law.
To ensure public safety and proper enforcement, the DGDA has requested that no LC or telegraphic transfer be opened for supplement imports without valid registration or prior authorization.
অর্থনৈতিক রিপোর্টার প্রকাশ : ২৯ এপ্রিল ২০২৬, ১৯: ৩৮ বাণিজ্যিক ব্যাংকগুলো ঔষধ প্রশাসন অধিদপ্তরের অনুমোদন ছাড়া সাপ্লিমেন্ট জাতীয় পণ্যের এলসি খুলতে পারবে না। সম্প্রতি স্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয় থেকে একটি প্রজ্ঞাপন জারির মধ্য দিয়ে এই নির্দেশনা
The ‘1 Nojor’ media platform is now live in beta, inviting users to explore and provide feedback as we continue to refine the experience.
